InnoCare Announces Important Urticaria Trial Approval in China
InnoCare has received CDE/NMPA clearance to initiate a Phase II/III study of its oral TYK2 inhibitor soficitinib (ICP-332) in...
Jon Napitupulu
Acrivon to Announce Clinical Updates for ACR-368, ACR-2316
In an ongoing Phase 1 dose-escalation study, ACR-2316, Acrivon’s WEE1/PKMYT1 inhibitor, showed pharmacodynamic target engagement at the first two...
Tenax Therapeutics Reveals Blinded Sample Size Assessment Data
Tenax’s blinded sample size re-estimation in its Phase 3 LEVEL study indicates the trial retains well over 90% power...
Breakthrough ADAPT Trial Enrollment Complete for Olastrocel
A completed safety review by an independent DSMB reported no significant adverse events, and enrollment has now closed in...
Tiziana’s Phase 2 Alzheimer’s Trial Doses First Patient
Tiziana Life SciencesLife Sciences has dosed the first patient in a randomized, placebo-controlled Phase 2 study of intranasal foralumab...
A Vulnerable Infant Gut: The Critical Need for Restoration
Across multiple infant cohorts, up to 24% of U.S. infants had no detectable Bifidobacterium, with the absence rising to...
Immunovant Announces Pricing for Sizable $550M Stock Sale
Immunovant priced an underwritten public offering of 26.2 million primary shares at $21.00 per share for anticipated gross proceeds...
Cullgen’s Pain Drug CG001419 Shows Positive Phase 1 Results
Phase 1 data in 78 healthy volunteers showed CG001419 was well tolerated across single- and multiple-ascending doses with no...
Remarkable Lorundrostat Trial Noted by JAMA Research Roundup
Lorundrostat cut automated office systolic blood pressure by a mean 16.9 mmHg at Week 6 and 19.0 mmHg at...
FDA Approves Uplizna, A New Hope for Myasthenia Gravis
FDA has approved inebilizumab-cdon (Uplizna) for generalized myasthenia gravis in adults who are anti-AChR and anti-MuSK antibody positive, based...